Sponsored / 7 Min Read
New Platform Will be the First of its Kind for the $33 Billion Medical Cann-a-bis Market(1)…
See why BYND Cannasoft Enterprises Inc. (BCAN) could be entering a phase of unprecedented growth as it introduces its new CRM platform.
BYND Cannasoft Enterprises Inc.
6 Reasons why BYND Cannasoft Enterprises Inc. (BCAN) could witness unprecedented growth within the next 12-months.
First of its kind:
BYND Cannasoft Enterprises Inc.'s new platform will be the first of its kind for the medical cann-a-bis field and the Company believes it will transform the industry into a more organized, accessible and price transparent market.(1)
Fast “Growing” Market:
The global cann-a-bis cultivation market size was valued at $323.9 billion in 2021 and is expected to expand at a staggering compound annual growth rate of 21.4% from 2022 to 2030. (2)
Recurring Revenue:
BYND Cannasoft Enterprises Inc. (BCAN) has been marketing its proprietary customer relationship management (CRM) software product to approximately 400 clients with a monthly recurring revenue model for close to 20 years.(4)
Acquisition News:
BYND Cannasoft Enterprises Inc. (BCAN) recently acquired a company which holds the patent pending intellectual property for a therapeutic device in a market that is expected to grow to over $19 billion by 2028. (5)
Insider Ownership:
As of 10/12/22 insiders of BYND Cannasoft Enterprises Inc. (BCAN) own over 64% of the company’s shares according to Finviz.com (6)
Potential Upside:
BYND Cannasoft Enterprises Inc. (BCAN) opened at $2.55 on 10/12/22 after being as high as $16.38 less than a month earlier on 9/19/22. Though it isn’t expected, this provides (BCAN) with a potential upside of 542% if a move back to its 52-week high were to happen according to the price history available on Barchart.com. (3)
BYND Cannasoft Enterprises Inc.
Way back in 1996, California became the first state in the U.S. to legalize cann-a-bis for medical use (7) – 10 years later, the cann-a-bis market was literally blazing up the charts and early action takers were becoming filthy rich.
Once the cann-a-bis stocks started moving, they didn’t stop – and from 2016 to 2018 more gains were made in the cann-a-bis market than almost any other market in the same 2 year period… (8)
Those who were early enough to the “Green Rush” (2016 – 2018) could have witnessed potential gains like this:
- Aurora Cann-a-bis - up 1,571% (8)
- Canopy Growth Corp - up 2,602% (8)
- MariMed - up 3,093% (8)
- Cronos Group - 3,313% (8)
- Namaste Technologies - 6,750% (8)
BYND Cannasoft Enterprises Inc.
A Better Way To Participate in the Booming Cann-a-bis Market?
Ancillary cann-a-bis stocks can provide a very attractive way to actively follow this growing industry.
There are ways to enter the booming cann-a-bis market without buying shares of companies directly involved in the growing or selling of the plant.
There are ways to speculate in the cann-a-bis market without buying shares of companies directly involved in the growing or selling of the plant.
These ancillary companies provide everything from hydroponic supplies necessary to grow cann-a-bis to online platforms that connect consumers with dispensaries.
One company that could be entering a phase of unprecedented growth as it introduces its new CRM platform is BYND Cannasoft Enterprises Inc.
BYND Cannasoft Enterprises Inc. (BCAN) is an integrated software/cann-a-bis company, based in Israel with a first of its kind platform for the $33 billion medical cann-a-bis market.
BYND Cannasoft Enterprises Inc. (BCAN) owns and markets a proprietary customer relationship management (CRM) software product, known as “Benefit CRM.” BYND’s Benefit CRM software enables small and medium‐sized businesses to optimize their day‐to‐day business activities such as sales management, personnel management, marketing, call center activities and asset management. BYND’s next-generation Benefit CRM platform is now ready for BETA testing.
Building on its 20 years of experience in CRM software, BYND Cannasoft Enterprises Inc. (BCAN) has recently begun development of an innovative new CRM platform, designed specifically to serve the needs of the medical cann-a-bis industry.
This new platform will be the first of its kind for the medical cann-a-bis field and the Company is confident it will transform the industry into a more organized, accessible, and price transparent market.
Data and information collected through the operation of the Cann-a-bis Farm (see below) and the products it produces will allow BYND to test its new Cann-a-bis CRM platform and adjust the platform as necessary.
Additionally, operating the Cann-a-bis Farm and selling medical cann-a-bis will bring in additional revenue to further support BYND during the initial roll‐out years of its cann-a-bis CRM platform.
BYND Cannasoft Enterprises Inc. (BCAN)’s CRM and ERP system is a state-of-the-art CRM designed with years of industry and market specific experience.
In its second generation, BYND Cannasoft Enterprises Inc. wishes to build tailored software for the cann-a-bis industry. The CRM and ERP system will be integrated into the company’s delivery and recommendation system to help manage inventory, create performance reports and financial reports.
BYND Cannasoft Enterprises Inc.
The Company’s plans include the construction of 4 state of the art greenhouses, housing approximately 2.5 acres of total growing area.
BYND Cannasoft Enterprises Inc. (BCAN) estimates that once fully operational its Cann-a-bis farm facility will be able to produce 7,500kg of raw cann-a-bis each year. BYND also intends to work with strategic partners to develop and market new, proprietary cann-a-bis infused products for sale throughout Israel and for export.
The company operates on 3 parallel levels as part of its plans to enter the market for growing and selling medical cann-a-bis:
1
2
3
BYND Cannasoft Enterprises Inc.
BYND Cannasoft Enterprises Inc. Announces Acquisition
The EZ-G device is a unique, patent-pending device that, combined with proprietary software (provisional application), regulates the flow of low-concentration C-B-D oils into the soft tissues of the female reproductive system.
According to research conducted across the globe, treatment with low-concentration C-B-D oils can relieve candida, dryness, scars, and many other female health issues.
BYND intends to pursue the final registration of the patent and establish a marketing and sales system for the EZ-G device.
The Company’s ‘Go to Market’ strategic plan is based on combined B2B and B2C sales. Numerous studies have shown C-B-D interacts with the endocanna-bi-noid system, a master regulatory system with receptors all around the body.
By activating these receptors, C-B-D can have health benefits that help make sex more approachable and pleasurable by reducing stress, enhancing one’s mood, promoting body comfort, and treating vaginal issues.
According to the Brightfield Group, a cann-a-bis industry data research firm, sales of C-B-D products could reach $11 billion by 2027. A recent Zion Market Research study indicates the market size of global gynecology devices was worth $10.8 billion in 2021 and is estimated to exceed $19.5 billion by 2028 with a compound annual growth rate (CAGR) of approximately 10.3 percent. (5)
No regulatory filings relating to the device have been made in the United States and the Company has no intention of marketing the device in any jurisdiction until it has been cleared by the applicable regulator, including the Food and Drug Administration in the United States.
Yftah Ben Yaackov, CEO and a Director of BYND, said,
"From the moment we complete the purchase of ZC, we plan to hit the ground running by initially securing any required regulatory approval from the appropriate authorities. We will continue to pursue the registration of the patent, which contain over 100 claims, prototype production and start validation tests, and contract with suppliers for the production of the device and the oils used in the EZ-G device. (5) “The demand for a unique device combined with software, such as the EZ-G device, stems from the increasing occurrence of chronic conditions and the rising adoption of self-health management. Using a device at home is a very cost-effective treatment, and it opens up a vast channel for millions of women." (5)
"We hope to use the knowledge we have gained in the medical cann-a-bis field to significantly improve the quality of life of women suffering from symptoms such as those mentioned above." (5)
Legitimizing the Cann-a-bis Industry
On Oct. 6, 2022, US president Joe Biden announced a series of steps toward easing the way the country enforces its mar-i-juana laws. In addition to pardoning people convicted on federal marijuana charges, his administration will be considering whether to reclassify mar-i-juana as a less serious drug. (9)
Changing mar-i-juana’s classification status could unlock an enormous growth spurt for the US cann-a-bis industry, already valued at $33 billion under current constraints. (9)
Mar-i-juana stocks shot up after Biden’s announcement, which could be the first step in bringing the sector out of the shadows and making it a more mainstream and taxable part of the US economy. (9)
Mar-i-juana is currently a Schedule I drug, the most severe classification the government uses. Drugs under this classification are considered to have a high likelihood of abuse and no medical uses. By contrast, co-caine and fent-anyl are Schedule II drugs, a lighter designation. (9)
Both Congress and the Biden administration have the ability to change mari-j-uana’s classification. The executive branch’s path is more complicated, needing a full review from both the Justice Department and the Department of Health and Human Services. (9)
Decriminalizing or legalizing mar-i-juana would be a job for Congress, not the president, though the executive branch could effectively stop prosecuting mar-i-juana crimes under federal law if it wanted to. (9)
In recent years, mar-i-juana policy has been largely a state issue: 19 states and the District of Columbia have fully legalized we-ed, while 38 have approved its medical use. A handful of states have decriminalized the drug without fully legalizing it. (9)
Cann-a-bis businesses such as dispensaries often operate as cash businesses. In 2014, the Treasury department clarified that under the Bank Secrecy Act, banks can provide services to pot-related companies, but many financial institutions remain reluctant to openly enter into relationships with state-authorized mar-i-juana businesses due to the Schedule I status of mar-i-juana. (9)
SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & INVESTOR NEWS.
Getting the Right News Before Everyone Else Does, is FREE...
BYND Cannasoft Enterprises Inc.
Strong Insider Ownership
In general, it’s good news when a stock has high insider ownership. If company insiders don’t even believe a stock has additional upside, it doesn’t bode well for outside investors. (11) Stocks with high insider ownership also might have lower floats, which means there are less shares free to trade on the public market. (11) This low supply can trigger much larger moves in share price if demand rises due to an earnings beat or other catalyst. (11)
According to Finviz.com, as of 10/12/22 insiders at BYND Cannasoft Enterprises Inc. (BCAN) own over 64% of the company’s shares according to Finviz.com (6)
Here are the other top 5 stocks with the highest insider ownership percentages, according FinViz as of 10/12/2022.
- T-Mobile US, Inc. (TMUS) 52.10%
- Hormel Foods Corporation (HRL) 47.43%
- Rollins, Inc. (ROL) 45.30%
- Oracle Corporation (ORCL) 42.70%
- Fox Corporation (FOX) 42.56%
BYND Cannasoft Enterprises Inc.
542% Potential Upside To Recent Highs
BYND Cannasoft Enterprises Inc. (BCAN) opened at $2.55 on 10/12/22 after being as high as $16.38 less than a month earlier on 9/19/22 representing a potential upside of 542% if a move back to its 52-week high were to happen according to the price history available on Barchart.com. (3) This upside move is not expected to happen, but readers should be aware that the potential exists.
Management Team
Moti Maram - President and Director
In 1986, Mr. Maram partnered to found a computer company that mainly provided services to EXATEC-compliant IBM AS 400 computers and sales and service to the first PCs in the world. After identifying a need for CRM and ERP software, Maram and his partner, Avner Tal, established a software company that manufactures CRM and ERP management software called BENEFIT in 2000.
Yftah Ben Yaackov - CEO and Director
Mr. Yaackov has been a professional lawyer since 2004. He specialized in real estate-related issues, including real estate corporations, complex sales transactions, real estate unions, and real estate taxation. His recent experience includes managing large projects exceeding tens of thousands of square meters with budgets exceeding 400 million NIS ($115 million). Over the last five years, Mr. Yaackov has assembled the business activity of two of the largest medical cannabis companies in Israel, providing him with tremendous experience and knowledge in this field.
Avner Tal - VP Sales & Marketing, CTO, and Director
Mr. Tal currently serves as the Technology Director of Beyond Solution Company. After studying electronics and control, he served in the Navy on the team that implemented and developed the technology that included "smart" missiles. He came to BYND Cannasoft Enterprises after working with Moti Maram to establish the computer company that supported Exatech computers and its innovative network.
Gabi Kabazo - CFO and Director
Gabi is a seasoned finance and operations professional with over 20 years of experience supporting accounting, finance, and IT operations in complex corporate settings. Since 2009, Mr. Kabazo has been with TELUS Telecommunications Company. From 2002-2011 he served as CFO for m-Wise Inc. He received B.A from TAU and M.B.A from UBC in Accounting & Economics.
Dr. Stefánia Szabó - Director
Dr. Szabó is the Vice President of Pace Law Firm and Director of International Relations at Pace Global Advantage in Toronto, Canada. She is a former diplomat, a charismatic government services, management, and public relations professional with 25 years of progressive experience. She is an international lawyer by profession and serves as a member of the Canada-Israel Chamber of Commerce executive committee.
Harold Wolkin - Director
Mr. Wolkin is a retired Investment Banker and Financial Analyst with over 40 years of business experience. As an esteemed advisor to Chief Executive Officers and Boards of both public and private companies, he provides BYND Cannasoft Enterprises with strong financial expertise. Mr. Wolkin holds the Chartered Financial Analyst (CFA) certification and is a member of the Institute of Corporate Directors.
Niv Shirazi - Director
Mr. Shirazi is a business professional with strong financial acumen. Since 2018, he has served as Chief Operating Officer with H.N. Win Ltd, an Israeli real estate firm. Mr. Shirazi received a B.A. in Business Administration and Accounting from the Ono Academic College in Kiryat Ono, Israel.
Gil Shapira - Greenhouse Facility Project Manager
Mr. Shapira is an engineer with more than 30 years of experience planning, managing, and implementing complex engineering projects. Operating locally and internationally, he continues to provide customized services to the pharmaceutical, biotechnological, medical device, health, and food industries. In his career, Mr. Shapira has designed thousands of square meters of production facilities, clean rooms, laboratories, and production equipment certified by the FDA, EMEA, GMP, GLP, FACT, NETCORD, JACIE, and the Israeli Ministry of Health.
Carmel Zigdon - Director
Carmel is the inventor of the EZ-G device and the previous owner of Zigi Carmel Initiatives & Investments. Since 2018, Carmel has served as the online shopping manager of ZCRAVE.com, an online clothes store that generates millions of dollars. In September of 2022, Carmel was appointed to the board of directors BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN).
New Platform Will be the First of its Kind for the $33 Billion Medical Cann-a-bis Market(1)…
See why BYND Cannasoft Enterprises Inc. (BCAN) could be entering a phase of unprecedented growth as it introduces its new CRM platform.
BYND Cannasoft Enterprises Inc.
6 Reasons why BYND Cannasoft Enterprises Inc. (BCAN) could witness unprecedented growth within the next 12-months.
First of its kind:
BYND Cannasoft Enterprises Inc.'s new platform will be the first of its kind for the medical cann-a-bis field and the Company believes it will transform the industry into a more organized, accessible and price transparent market.(1)
Fast “Growing” Market:
The global cann-a-bis cultivation market size was valued at $323.9 billion in 2021 and is expected to expand at a staggering compound annual growth rate of 21.4% from 2022 to 2030. (2)
Recurring Revenue:
BYND Cannasoft Enterprises Inc. (BCAN) has been marketing its proprietary customer relationship management (CRM) software product to approximately 400 clients with a monthly recurring revenue model for close to 20 years.(4)
Acquisition News:
BYND Cannasoft Enterprises Inc. (BCAN) recently acquired a company which holds the patent pending intellectual property for a therapeutic device in a market that is expected to grow to over $19 billion by 2028. (5)
Insider Ownership:
As of 10/12/22 insiders of BYND Cannasoft Enterprises Inc. (BCAN) own over 64% of the company’s shares according to Finviz.com (6)
Potential Upside:
BYND Cannasoft Enterprises Inc. (BCAN) opened at $2.55 on 10/12/22 after being as high as $16.38 less than a month earlier on 9/19/22. Though it isn’t expected, this provides (BCAN) with a potential upside of 542% if a move back to its 52-week high were to happen according to the price history available on Barchart.com. (3)
Source 1: https://www.thenewswire.com/press-releases/1kogF5wvn-bynd-cannasoft-enterprises-inc-to-commence-trading-on-nasdaq-stock-exchange.html
Source 2: https://bit.ly/3g53ke3
Source 3: https://www.barchart.com/stocks/quotes/BCAN/price-history/historical
Source 4: https://bit.ly/3Muea9w
Source 5: https://finance.yahoo.com/news/bynd-cannasoft-enterprises-inc-signs-020500859.html
Source 6: https://finviz.com/quote.ashx?t=BCAN&p=d
Source 7: https://bit.ly/3uxSGkp
Source 8: https://bit.ly/2zz5WYB
Source 9: https://qz.com/emails/quartz-at-work/1849646943/menopause-the-cost-of-company-ignorance
Source 10: https://schrts.co/tiuzciND
Source 11: https://www.yahoo.com/now/16-p-500-stocks-most-161052263.html